This workflow, named Forestwalk, uncovered pharmacological treatment effects in C57BL/6J mice, revealed phenotypes in transgenic mice used to study Angelman syndrome and SLC6A1‐related neurodevelopmental disorder, and will facilitate a deeper understanding of how the brain controls balance in health and disease. Here, SLC6A1 is linked to Angelman syndrome.